SRPT Q1 2024 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$413M+63.1% YoY

Gross Profit

$363M87.8% margin

Operating Income

$35M8.4% margin

Net Income

$36M8.7% margin

EPS (Diluted)

$0.37

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

-$242M

Free Cash Flow

-$285M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$2.3B

Stockholders' Equity

$961M

Cash & Equivalents

$427M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$413M	$254M	+63.1%
Gross Profit	$363M	$218M	+66.1%
Operating Income	$35M	-$138M	+125.3%
Net Income	$36M	-$517M	+107.0%

Geographic Segments

UNITED STATES

$190M84%

Rest of World

$36M16%